Overview

A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice

Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study.
Phase:
Phase 3
Details
Lead Sponsor:
bioRASI, LLC
Mayne Pharma International Pty Ltd
Collaborator:
bioRASI, LLC
Treatments:
Ivermectin